The relationship between Uric Acid with cytokines, CRP and their effect on gout patients in Thi-Qar Governorate

Kareema A. Dakhil, Manal A. Aziz, Wajdy J. Majid

Abstract


Background: Gout is thought to be an autoinflammatory illness because monosodium urate (MSU) crystals trigger the activation of NLRP3 inflammasome, which in turn triggers caspase-1 to release active cytokines. Yet, it is still unclear how blood cytokine levels relate to the symptoms and clinical indicators of the illness. The serum levels of Interleukin-6 (IL-6), Adiponectin (ADP), C-Reactive Protein (CRP), and Uric Acid (UA) were examined, and their relationship with clinical and laboratory findings was discussed.

Methods: ELISA was used to determine the clinical, laboratory, and cytokine levels of 80 male and female gout patients (gout group). The study also included 70 individuals without a history of arthritis for comparison.

Results: On analysis, 80 out of the 150 individuals had gout arthritis. Uric Acid, IL-6, and CRP concentrations were all noticeably more prevalent in patients than in the control group (P < 0.001). Furthermore, ADP levels in patients were considerably lower than those of the control group (P < 0.001) as well. The present results were examined for age, gender, and body mass index (BMI).

Conclusion: High mean levels of UA, CRP, and IL-6, in both male and female gouty patients, as well as low mean values of ADP, were discovered when biochemical parameters were evaluated. As a result, UA, IL-6, ADP, and CRP are concluded to be significant markers for the development of gout-related comorbidities and are key gout predictors.

Keywords: Gout, Uric Acid (UA), Interleukin-6 (IL-6), C-Reactive Protein (CRP), Adiponectin (ADP), Inflammation


Full Text:

PDF

References


Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology, (2020); 16(7): 380-390.

Singh JA, Gaffo A. Gout epidemiology and comorbidities. Seminars in arthritis and rheumatism. (2020); 50(3): S11-S16.

Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nature reviews rheumatology, (2015); 11(11): 649-662.

Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout. Drugs, (2006); 66(2006): 1547-1563.

Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, (2006); 440(7081): 237-241.

Terkeltaub R. What makes gouty inflammation so variable?. BMC medicine, (2017); 15(2017): 1-10.

Rothenbacher D, Kleiner A, Koenig W, Primatesta P, Breitling LP, et al. Relationship between Inflammatory Cytokines and Uric Acid Levels with Adverse Cardiovascular Outcomes in Patients with Stable Coronary Heart Disease. PLoS ONE, (2012); 7(9): 1-8.

Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin‐6 production and secretion by human monocytes and synoviocytes. Arthritis & Rheumatism, (1989); 32(11): 1443-1452.

Braun T, Schett G. Pathways for bone loss in inflammatory disease. Current osteoporosis reports, (2012); 10(2012): 101-108.

Zhang Z, Wang P, Xiong Q, Xu S, Kang D, et al. Advancements in the study of IL-6 and its receptors in the pathogenesis of gout. Cytokine, (2024); 182(2024): 1-9.

Cavalcanti NG, Marques CD, Lins e Lins TU, Pereira MC, Rêgo MJ, et al. Cytokine profile in gout: inflammation driven by IL-6 and IL-18?. Immunological investigations, (2016); 45(5): 383-395.

Swaak AJ, Rooyen AV, Nieuwenhuis E, Aarden LA. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scandinavian journal of rheumatology, (1988); 17(6): 469-474.

Cong R, Zhang X, Song Z, Chen S, Liu G, et al. Assessing the causal effects of adipokines on uric acid and gout: A two-sample mendelian randomization study. Nutrients, (2022); 14(5): 1-11.

Orlova IV, Stanislavchuk MA. Clinical significance of adipokine profile (leptin and adiponectin) in patients with gout. PAIN, JOINTS, SPINE, (2023); 13(2): 108-115.

Maeda N, Funahashi T, Matsuzawa Y, Shimomura I. Adiponectin, a unique adipocyte-derived factor beyond hormones. Atherosclerosis, (2020); 292(2020): 1-9.

Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS letters, (2005); 579(2): 295-301.

Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature reviews immunology, (2006); 6(10): 772-783.

Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid–induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology, (2005); 16(12): 3553-3562.

Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. American Journal of Physiology-Cell Physiology, (2007); 293(2): C584-C596.

Han L, Zhang L, Hu W, Lu Y, Wang Z. Association of C-reactive protein with all-cause and cause-specific mortality in people with gout. European Journal of Medical Research, (2024); 29(1): 1-10.

Tagoe CE, Raza Y. Differences in acute phase reactants between gout and pseudogout. International Journal of Clinical Medicine, (2013); 4(12): 13-19.

Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. International journal of biological sciences, (2012); 8(9): 1237–1247.

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension, (2003); 41(6): 1183-1190.

Zha X, Yang B, Xia G, Wang S. Combination of uric acid and pro-inflammatory cytokines in discriminating patients with gout from healthy controls. Journal of inflammation research, (2022); 15(2022): 1413-1420.

Janssens HJ, Fransen J, Van de Lisdonk EH, van Riel PL, van Weel C, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Archives of internal medicine, (2010); 170(13): 1120-1126.

Bernal JA, Quilis N, Andrés M, Sivera F, Pascual E. Gout: optimizing treatment to achieve a disease cure. Therapeutic advances in chronic disease, (2016); 7(2): 135-144.

Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Annals of the rheumatic diseases, (2013); 72(5): 694-700.

Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. The American Journal of Managed Care, (2005); 11(15 Suppl): S435-S442.

Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC musculoskeletal disorders, (2011); 12(2017): 1-7.

Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC medicine, (2017); 15(2017): 1-10.

Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. The American journal of medicine, (2007); 120(5): 442-447.

Stamp L, Dalbeth N. Screening for hyperuricaemia and gout: a perspective and research agenda. Nature Reviews Rheumatology, (2014); 10(12): 752-756.

Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nature Reviews Rheumatology, (2013); 9(1): 13-23.

Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis & Rheumatism, (1977); 20(3): 895-900.

Schlesinger N. Diagnosing and treating gout: a review to aid primary care physicians. Postgraduate medicine, (2010); 122(2): 157-161.

Cabău G, Crișan TO, Klück V, Popp RA, Joosten LA. Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunological reviews, (2020); 294(1): 92-105.

Jiang X, Li M, Yang Q, Du L, Du J, et al. Oxidized low density lipoprotein and inflammation in gout patients. Cell Biochemistry and Biophysics, (2014); 69(2014): 65-69.

Higgins P, Dawson J, Walters M. The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovascular Psychiatry and Neurology, (2009); 2009(1): 1-9.

Jin M, Yang F, Yang I, Yin Y, Luo JJ, et al. Uric acid, hyperuricemia and vascular diseases. Frontiers in Bioscience: A Journal and Virtual Library, (2012); 17(2012): 656–669.

Tang Y. Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation–United States, 2010-2012. Morbidity and Mortality Weekly Report, (2013); 62(44): 869–873.

Lenski M, Scherer MA. Analysis of synovial inflammatory markers to differ infectious from gouty arthritis. Clinical Biochemistry, (2014); 47(1-2): 49-55.




DOI: http://dx.doi.org/10.62940/als.v12i3.2308

Refbacks

  • There are currently no refbacks.